Questions About Cancer? 1-800-4-CANCER

Nausea and Vomiting (PDQ®)

Health Professional Version

Changes to This Summary (03/12/2015)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Prevention of Acute/Delayed Nausea and Vomiting (Emesis)

Added text to state that another randomized phase III trial studied the use of aprepitant, granisetron, and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in multiple myeloma autologous stem cell transplant patients receiving melphalan, and that statistically positive benefit was seen in patients given this regimen, compared with granisetron and dexamethasone alone, without an increase in side effects (cited Schmitt et al. as reference 67).

This summary is written and maintained by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: March 12, 2015